Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

• मुख्य लेखकों: Ekaterina Gibiansky (लेखक), Leonid Gibiansky (लेखक), Clarisse Chavanne (लेखक), Nicolas Frey (लेखक), Candice Jamois (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2021-08-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract A subcutaneous formulation of the anti‐CD20 antibody rituximab has been developed. Fixed‐dose subcutaneous rituximab delivers noninferior serum trough concentrations (Ctrough), ensuring similar target saturation and comparable efficacy/safety, to intravenous rituximab, but with simplified a...